SCHEMBL748440

SCHEMBL748440

O=[PH](O)OC(Cl)(Cl)O[PH](=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11768917 0.97
SCHEMBL8076384 0.97
SCHEMBL8077989 0.97
Diethylamine SCHEMBL8078238 0.81 TP53 (0.35)
SCHEMBL17061029 0.80
Pyridine SCHEMBL8078245 0.79 TSHR (0.38)
SCHEMBL28244105 0.75
SCHEMBL17696695 0.75
SCHEMBL28574527 0.73
SCHEMBL4487116 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705500-A2 REAGENT USED IN DEPROTECTION OF 3'-O-AMINO POLYNUCLEOTIDES DNA Script (FR) 2026-03-11 EP claimed
WO-2024227846-A2 REAGENT USED IN DEPROTECTION OF 3'-O-AMINO POLYNUCLEOTIDES DNA SCRIPT (FR) 2024-11-07 WO claimed
US-20240368656-A1 REAGENTS AND METHODS USED IN DEPROTECTION OF 3'-O-AMINO POLYNUCLEOTIDES DNA SCRIPT (FR) 2024-11-07 US claimed
US-20180185487-A1 METHOD TO ACHIEVE EXTENDED EXPRESSION OF DNA INFUSED INTO LIVER IMMUSOFT CORPORATION 2018-07-05 US claimed
US-20140141065-A1 METHOD TO ACHIEVE EXTENDED EXPRESSION OF DNA INFUSED INTO LIVER IMMUSOFT CORPORATION 2014-05-22 US claimed
CN-100364544-C Gelatin micro-particles carried with dichloromethylene diphosphonate, and its prepn. method RUIJIN HOSPITAL ATTACHED TO SH (CN) 2008-01-30 CN claimed
US-20070218116-A1 Compositions and methods for the treatment of tumors and tumor metastases SCHWENDENER RETO A 2007-09-20 US claimed
US-20070044165-A1 Non-human mammal model comprising heterologous nucleated cells - use for screening compounds INSTITUT PASTEUR (FR) 2007-02-22 US claimed
EP-1708566-A1 NON-HUMAN MAMMAL MODEL COMPRISING HETEROLOGOUS NUCLEATED CELLS-USE FOR SCREENING COMPOUNDS INSTITUT PASTEUR (FR) 2006-10-11 EP claimed
EP-1701612-A2 CHIMERIC MURINE MODEL COMPRISING HUMAN HEPATOCYTES USER FOR SCREENING COMPOUNDS INSTITUT PASTEUR (FR) 2006-09-20 EP claimed
US-6770260-B1 MAMMAL MODEL CONTAINS A DECREASED LEVEL OF ENDOGENOUS MACROPHAGES SUFFICIENT TO REDUCE DEPLETION OF NON-AUTOLOGOUS HEMATOPOIETIC CELLS, ACHIEVED BY ADMINISTERING AN EFFECTIVE AMOUNT OF DICHLOROMETHYLENE DIPHOSPHONATE NOVARTIS AG (CH) 2004-08-03 US claimed
CN-1150200-C Process for preparing methylene bisphosphonates 2004-05-19 CN claimed
CN-1124130-C Pharmaceutical formulation comprising a clodronate active ingredient and a silicified microcrystalline cellulose excipient LEIRAS OY (FI) 2003-10-15 CN claimed
CN-1121875-C Pharmaceutical composition suitable for freeze drying ASTRA PHARMA PROD (GB) 2003-09-24 CN claimed
US-20030118637-A1 Composition and method for treating autoimmune hemolytic anemia NATIONAL JEWISH MEDICAL AND RESEARCH CENTER 2003-06-26 US claimed
CN-1371383-A Process for preparing methylene bisphosphonic and salts ASTRAZENECA UK LTD (GB) 2002-09-25 CN claimed
CN-1270516-A Pharmaceutical preparation comprising colodronate as active ingredient and silicified microcrystalline cellulose as excipient LEIRAS OY (FI) 2000-10-18 CN claimed
US-5932563-A Methods for treating spinal cord injury OHIO STATE RESEARCH FOUNDATION (US) 1999-08-03 US claimed
EP-0787003-A2 USE OF MACROPHAGE DEPLETING AGENTS FOR PROLONGING THE SURVIVAL OF NON-AUTOLOGUS HEMATOPOIETIC CELL TRANSPLANTS AND ANIMAL MODEL ASSAY SYSTEMS Novartis AG (CH) 1997-08-06 EP claimed
WO-1995016452-A2 USE OF MACROPHAGE DEPLETING AGENTS FOR PROLONGING THE SURVIVAL OF NON-AUTOLOGUS HEMATOPOIETIC CELL TRANSPLANTS AND ANIMAL MODEL ASSAY SYSTEMS SYSTEMIX INC. (US) 1995-06-22 WO claimed